Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026

Same author

Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

Nature communications·2026

Same author

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Frontiers in immunology·2026

Same author

The contribution of rare germline variants to the immune landscape of breast cancer.

Genome medicine·2026

Same author

Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?

Breast cancer research and treatment·2026

Same author

Progress toward personalized management of stage II/III triple negative breast cancer.

Cancer treatment reviews·2026

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Neoadjuvant immunotherapy in breast cancer: Progress and challenges.

Manon de Graaf¹, Alex De Caluwé², Laurence Buisseret³

¹Department of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Trends in Cancer

|July 14, 2026

Summary

Neoadjuvant immunotherapy shows promise for breast cancer (BC), but not all patients benefit. Biomarkers are needed to personalize treatment, balancing efficacy and toxicity for better outcomes in BC immunotherapy.

Keywords:

breast cancer immune checkpoint inhibition neoadjuvant

Related Experiment Videos

Last Updated: Jul 16, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

Oncology
Immunotherapy
Breast Cancer Research

Background:

Breast cancer (BC) was historically viewed as an 'immunologically cold' tumor.
Anti-programmed cell death protein 1 (PD-1) therapies have emerged as a significant advancement, particularly in triple-negative breast cancer.
Promising results from neoadjuvant Phase III trials are also seen in high-grade estrogen receptor-positive breast cancer.

Purpose of the Study:

To review the current status of neoadjuvant immunotherapy in breast cancer.
To identify challenges in current neoadjuvant immunotherapy approaches for breast cancer.
To highlight the need for biomarkers to guide personalized treatment strategies.

Main Methods:

Literature review of neoadjuvant immunotherapy in breast cancer.
Analysis of clinical trial data for anti-PD-1 therapies in breast cancer.
Discussion of biomarker development for immunotherapy response prediction.

Main Results:

Anti-PD-1 therapy has transformed treatment for triple-negative breast cancer.
Neoadjuvant immunotherapy shows potential in high-grade estrogen receptor-positive breast cancer.
A significant subset of patients do not respond to current immunotherapy, necessitating combination strategies.

Conclusions:

Neoadjuvant immunotherapy offers new hope for breast cancer patients.
There is a critical need for prognostic and predictive biomarkers to optimize treatment selection.
Balancing treatment efficacy with toxicity is essential for improving patient outcomes and avoiding overtreatment.